Biogen has announced that it will discontinue the commercialization of Aduhelm, its contentious medication for Alzheimer’s disease.
Biogen has announced that it will discontinue sales of its Alzheimer’s medication Aduhelm. This drug was previously expected to be a major success, but faced setbacks after its initial release. On Wednesday, the pharmaceutical company announced that it will discontinue a trial for the medication required for complete authorization from the Food and Drug Administration.
READ MORE